IRF1 and neoplasm: The tumor tissue slides showed all therapeutic groups contained sufficient amount of MNFs inside the tumor (Supplementary Fig. 8), and the remarkable therapeutic outcome can be attributed to the synergistic effects of GLUT-1 inhibition and the increase in IRF-1, which leads to downregulation of RAD51 expression (Fig. 6a).